SHARESIFT
Healthcare · data ~15-min delayed
11,870 GBp -1.35%
| Price | 11,870 GBp |
| Day change | -1.35% |
| Market cap | 184.09B |
| 52-week range | 9,892 – 15,732 |
| P/E (trailing) | 23.6 |
| Dividend yield | 2.01% |
| Payout ratio | 47.41% |
| Return on equity | 21.96% |
| Debt / equity | 64% |
| Beta | 0.20 |
| Sector | Healthcare |
| Value score | 43 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
AstraZeneca PLC (AZN.L) scores 43/100 on this site's value model, a middling reading with some valuation measures favourable and others not. It trades at 23.6 times trailing earnings and is classified in Healthcare. The dividend yield is 2.01%, paid from 47% of earnings. Return on equity is 22%, with debt at 64% of equity. On its filings it passes 8 of the nine Piotroski checks, which points to improving fundamentals. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 8 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 3.25 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: UK stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.